Cost‐Effectiveness Analysis of Hormone Therapy for Breast Cancer in Japan
Asia-Pacific Journal of Clinical Oncology · 2026
DOI: 10.1111/ajco.70084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2026. Verfasst von Naoto Nakagawa und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Ohu University, Koriyama, Fukushima, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Anastrozole, Tamoxifen, Antineoplastic Agents, Hormonal. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Breast cancer is one of the deadliest diseases in the world. It accounts for 22.2% of all cancers and is the most common site of cancer in women in Japan. Although hormone therapy with aromatase inhibitors or tamoxifen has been widely used, it is unclear which agent is more cost‐effective. This study examined the cost‐effectiveness of anastrozole as an aromatase inhibitor from a healthcare payer's perspective compared to tamoxifen in Japan.
Methods
A Markov model, for comparing anastrozole with tamoxifen as a reference agent, was developed using data from a randomized clinical trial conducted in Japan. The costs were derived from the Japanese health care fee index for 2022. Based on the results of a questionnaire on the general health‐related quality of life associated with cancer (FACT‐G), utilities were converted to EuroQol‐5 Dimension‐5 Level. The time horizon was set to 10 years. In addition, deterministic and probabilistic sensitivity analyses were conducted.
Results
Anastrozole was dominated by tamoxifen. Deterministic one‐way sensitivty analysis showed the expected value (EV) of incremental net monetary benefit for anastrozole was the highest sensitive to the pharmaceutical “drug price of anastrozole in fiscal year (FY) 2022,” where the generic drug price was applied. The EV remained negative across the other parameters. Probabilistic sensitivity analysis revealed that anastrozole dominance over tamoxifen was 47.2%.
Conclusion
Anastrozole was less cost‐effective than tamoxifen in Japan. Our findings support clinical practice and suggest that payers and policymakers should promote cost‐effective therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Ohu University, Koriyama, Fukushima, Japan.
- College of Pharmacy, Kaohsiung Medical University, Kaohsiung City, Taiwan.
Zitieren
APA
Nakagawa, N., Chiba, Y., & Lai, L. (2026). Cost‐Effectiveness Analysis of Hormone Therapy for Breast Cancer in Japan. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70084
Vancouver
Nakagawa N, Chiba Y, Lai L. Cost‐Effectiveness Analysis of Hormone Therapy for Breast Cancer in Japan. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70084
BibTeX
@article{Nakagawa2026,
author = {Nakagawa, Naoto and Chiba, Yuta and Lai, Leanne},
title = {Cost‐Effectiveness Analysis of Hormone Therapy for Breast Cancer in Japan},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70084}
}
EUVIMED